Composition containing sesamin lignan compounds and use thereof

Abstract

The application discloses a composition containing sesame lignan compounds and application thereof, and selects at least one of sesame lignan or similar compounds, glycoside compounds as a main active ingredient, so that the obtained composition can significantly improve physiological activities in the aspects of controlling fat in vivo, regulating intestinal flora, maintaining blood fat, blood sugar, blood pressure, protecting liver, controlling appetite, antioxidation and anti-aging, etc. Compared with single components, two or more than two compound combinations have a better synergistic effect. Meanwhile, the components in the composition are pure natural plant food raw materials, and have no toxic side effects. Therefore, the composition has a good application prospect.

Description

Compositions containing sesame lignans and their applications Technical Field

[0001] This invention relates to the fields of health food and biomedicine, and more specifically, to compositions containing sesame lignans and their applications. Background Technology

[0002] Sesame, also known as flaxseed, is an annual erect herbaceous plant belonging to the Pedaliaceae family and is one of the oldest oil crops. Originally from India and Africa, sesame is widely distributed in tropical and some temperate regions. Sesame production is mainly concentrated in Asia and Africa, with Asia accounting for approximately 67% of the world's sesame cultivation area.

[0003] Current research includes numerous studies on the structural identification of sesame lignans and the in vitro and in vivo efficacy studies of sesamin and sesamol in antioxidation, antitumor activity, neuroprotection, and anti-inflammation. However, systematic reports have not been published on the structure-activity relationships, rational combinations, scientific formulations, and related applications of sesame lignans and their similar compounds and glycosides.

[0004] In view of this, the present invention is proposed. Summary of the Invention

[0005] The purpose of this invention is to provide a composition containing sesame lignans and its application. This composition, by combining specific sesame lignans, can synergistically improve the effects of controlling body fat, regulating intestinal flora, maintaining blood lipids / blood sugar / blood pressure, protecting the liver, controlling appetite, anti-oxidation, and anti-aging.

[0006] This invention is implemented as follows:

[0007] In a first aspect, the present invention provides a composition containing sesame lignan compounds, comprising at least one of sesamolin, sesamol, sesamin, episamolin, pinoresinol, sesamolinol, menthol, 2-epesamolinol, sesamol triglucoside, and pinoresinol triglucoside.

[0008] Secondly, the present invention provides the use of the above composition in the preparation of products for controlling body weight and suppressing appetite.

[0009] Thirdly, the present invention provides the use of the above composition in the preparation of products for maintaining intestinal health.

[0010] Fourthly, the present invention provides the use of the above composition in the preparation of a medicament for improving insulin resistance and lowering blood sugar.

[0011] Fifthly, the present invention provides the application of the above composition in the preparation of products that lower body fat and blood lipids.

[0012] In a sixth aspect, the present invention provides the use of the above composition in the preparation of products that improve liver damage.

[0013] In a seventh aspect, the present invention provides the use of the above composition in the preparation of products for maintaining blood pressure.

[0014] Eighthly, the present invention provides the use of the above-described composition in the preparation of antioxidant and / or anti-aging products.

[0015] The present invention has the following beneficial effects:

[0016] This invention selects at least one of sesame lignans or similar compounds and glycosides as the main active ingredient, resulting in a composition that significantly enhances physiological activities such as controlling body fat, regulating intestinal flora, maintaining blood lipids / blood sugar / blood pressure, protecting the liver, controlling appetite, anti-oxidation, and anti-aging. The combination of two or more compounds exhibits a better synergistic effect compared to a single component; furthermore, all components in this composition are pure natural plant-based food ingredients with no toxic side effects; therefore, the composition of this invention has promising application prospects. Attached Figure Description

[0017] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings used in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of the present invention and should not be regarded as a limitation on the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort.

[0018] Figure 1 shows the structural formula of sesamin;

[0019] Figure 2 shows the structural formula of sesamol;

[0020] Figure 3 shows the structural formula of sesamin;

[0021] Figure 4 shows the structural formula of sesamin;

[0022] Figure 5 shows the structural formula of sesaminol;

[0023] Figure 6 shows the structural formula of sesangolin;

[0024] Figure 7 shows the structural formula of 7-episesantalin;

[0025] Figure 8 shows the structural formula of pinoresinol;

[0026] Figure 9 shows the structural formula of menthol;

[0027] Figure 10 shows the structural formula of sesamolinol;

[0028] Figure 11 shows the structural formula of 2-episesalatin;

[0029] Figure 12 shows the structural formula of 8-episesaminone;

[0030] Figure 13 shows the structural formula of sesamol triglucoside;

[0031] Figure 14 shows the structural formula of pinoresinol triglucoside. Detailed Implementation

[0032] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.

[0033] The present invention provides a composition in which the active ingredient is derived from sesame lignan compounds.

[0034] In this invention, sesamoid lignans refer to sesamoid lignans or their similar compounds and glycosides. Sesamoid lignans and their similar compounds may include: sesamol, sesamolin, sesamin, episesamolin, episesamolinol, sesangolin (a term specific to this field with no corresponding Chinese name), 7-episesantalin (a term specific to this field with no corresponding Chinese name), pinoresinol, menthol, sesamolinol, 2-episesalatin (a term specific to this field with no corresponding Chinese name), 8-episesaminone (a term specific to this field with no corresponding Chinese name), 2-episesalatin, 6-episesalatin, (-)-sesamolin, and (-)-episesinol. Sesamoid lignan glycosides may include sesamol triglucoside, sesamol diglucoside, sesamol monoglucoside, pinoresinol monoglucoside, and pinoresinol diglucoside pinoresinol triglucoside.

[0035] The components of the composition of the present invention are selected from at least one of the above-mentioned sesame lignans and their similar compounds, and glycoside compounds. For example, the composition contains at least one of sesamolin, sesamin, sesamin, episamolin, pinoresinol, sesamolinol, menthol, 2-epesamolinol, sesaminol triglucoside, or pinoresinol triglucoside.

[0036] The sesame lignan compounds of the present invention can be derived from sesame oil, sesame leaves, sesame seeds or sesame meal. They can be obtained by using existing preparation methods or by directly using commercially available related products. The present invention does not limit their source or preparation method.

[0037] In this invention, sesamolin and its similar compounds specifically include: sesaminol (CAS: 74061-79-3), and derivatives including sesamolin (CAS: 526-07-8), sesamin (CAS: 607-80-7), episisamin (CAS: 133-03-9), episaminol, sesangolin (CAS: 100268-57-3), 7-episesantalin, pinoresinol (CAS: 487-36-5), piperitol (CAS: 52151-92-5), and sesamoli. The compounds listed include nol (CAS:100016-94-2), 2-episesalatin (CAS:77449-32-2), 8-episesaminone, 2-episesaminol (CAS:104319-96-2), 6-episesaminol (CAS:105616-55-5), (-)-sesamin (-)-Sesamin (CAS:13079-95-3), and (-)-epipinoresinol (-)-Epipinoresinol (CAS:10061-38-8), some of which are shown in Figure 1-12. The specific sesame lignan glycoside compound is: sesaminol triglucan. The structures of some of the compounds, including triglucoside (CAS: 157469-83-5), sesaminol diglucoside (CAS: 157469-82-4 and 474431-66-8), sesaminol monoglucoside, pinoresinol monoglucoside, pinoresinol diglucoside, and pinoresinol triglucoside (CAS: 150035-90-8), are shown in Figures 13-14.

[0038] Preferably, the components of the composition of the present invention are selected from at least two of the above-mentioned sesame lignan compounds. During the experiments, the inventors found that although the above-mentioned compounds have varying degrees of effects in improving the control of body fat, regulating intestinal flora, maintaining blood lipids / blood sugar / blood pressure, protecting the liver, controlling appetite, anti-oxidation, and anti-aging, only some compounds have synergistic potential when combined, such as the combination of sesamolin and sesamin; or the combination of sesamolin and sesamol triglucoside.

[0039] The above-mentioned sesame lignan compounds, whether alone or in any combination of two, exhibit good physiological activity. Preferably, when the composition consists of sesamolin and sesamin, the mass ratio is 1-9: 9-1; when the composition consists of sesamolin and sesamin triglucoside, the mass ratio is 2-8: 8-2.

[0040] During the experiments, it was found that compositions prepared from at least one of the above-mentioned sesame lignan compounds can synergistically enhance physiological activities in controlling body fat, regulating intestinal flora, maintaining blood lipids / blood sugar / blood pressure, protecting the liver, controlling appetite, anti-oxidation, and anti-aging. Therefore, the compositions of the present invention have multiple applications, such as:

[0041] (1) Control weight or prepare weight control products.

[0042] (2) Suppress appetite or prepare products that suppress appetite; its specific effects include: regulating gastrointestinal hormone peptide levels and reducing food intake.

[0043] (3) Maintaining gut health or preparing products that maintain gut health; its specific effects include: reducing tumor necrosis factor-α and serum lipopolysaccharide levels.

[0044] (4) Improve insulin resistance and lower blood sugar, or prepare drugs that improve insulin resistance and lower blood sugar.

[0045] (5) Lowering lipids or preparing lipid-lowering products; its specific effects include: reducing body fat, epididymal fat, liver fat, groin fat and blood lipids; more specifically, its effects include lowering serum triglycerides, total cholesterol, low-density lipoprotein cholesterol; regulating the expression levels of leptin, adiponectin and liver peroxisome proliferator-activated receptor γ.

[0046] (6) Improve liver damage or prepare products that improve liver damage; its specific effects include: reducing serum aspartate aminotransferase activity.

[0047] (7) To maintain blood pressure or to prepare products for maintaining blood pressure.

[0048] (8) Antioxidant, anti-aging or preparation of antioxidant and / or anti-aging products; its antioxidant properties specifically include increasing the activity of superoxide dismutase and catalase and reducing the content of malondialdehyde.

[0049] The products mentioned in the above applications include, but are not limited to, health foods, pharmaceuticals, feed, and feed additives.

[0050] The features and performance of the present invention will be further described in detail below with reference to embodiments.

[0051] The sesamolin, sesaminol, sesamin, episamolin, pinoresinol, sesamolinol, menthol, 2-epesamolinol, sesaminol triglucoside, and pinoresinol triglucoside used in the embodiments of the present invention were all purchased from Aladdin, Shanghai Yuanye Biotechnology Co., Ltd., and Sigma Reagent Co., Ltd.

[0052] Example 1

[0053] This embodiment provides a composition in which the active ingredient is sesamin.

[0054] Example 2

[0055] This embodiment provides a composition in which the active ingredient is sesamol.

[0056] Example 3

[0057] This embodiment provides a composition in which the active ingredient is sesamin.

[0058] Example 4

[0059] This embodiment provides a composition in which the active ingredient is epissamin.

[0060] Example 5

[0061] This embodiment provides a composition in which the active ingredient is pinoresinol.

[0062] Example 6

[0063] This embodiment provides a composition in which the active ingredient is sesamolinol.

[0064] Example 7

[0065] This embodiment provides a composition in which the active ingredient is menthol.

[0066] Example 8

[0067] This embodiment provides a composition in which the active ingredient is 2-episaritol.

[0068] Example 9

[0069] This embodiment provides a composition in which the active ingredient is sesamol triglucoside.

[0070] Example 10

[0071] This embodiment provides a composition in which the active ingredient is pinoresinol triglucoside.

[0072] Example 11

[0073] This embodiment provides a composition comprising the following components: sesamin and sesamin in a mass ratio of 1:9.

[0074] Example 12

[0075] This embodiment provides a composition comprising the following components: sesamin and sesamin in a mass ratio of 9:1.

[0076] Example 13

[0077] This embodiment provides a composition comprising the following components: sesamin and sesamol triglucoside in a mass ratio of 2:8.

[0078] Example 14

[0079] This embodiment provides a composition comprising the following components: sesamin and sesamol triglucoside in a mass ratio of 8:2.

[0080] Comparative Example 1

[0081] The difference between the composition of this comparative example and that of Example 11 is that an equal amount of menthol is used instead of sesamin.

[0082] All functional evaluation schemes were implemented in accordance with the "Methods for Functional Testing and Evaluation of Health Foods (2023 Edition)" issued by the National Health Commission.

[0083] Experimental Example 1

[0084] The effects of the compositions of Examples 1-14 and Comparative Example 1 on weight loss, appetite control, and improved gut health were verified. The specific methods are as follows:

[0085] High-fat diet mouse model: 4-week-old healthy male C57BL / 6 mice (SPF grade) were used as experimental animals. There were 12 mice in 3 cages in each treatment group. They had free access to food and water. The experimental period was 8 weeks.

[0086] The experimental groups are as follows:

[0087] (1) The control group (CHOW) was fed a normal maintenance diet;

[0088] (2) The high-fat diet model group (HFD) was fed a commercial high-fat diet (purified high-fat diet with a fat energy ratio of 45%).

[0089] (3) The experimental intervention group was fed a commercially available high-fat diet with the same energy, and the diet was supplemented with the compositions of Examples 1-14 and Comparative Example 1 at a dose of 1000 mg / kg.

[0090] Mouse model of compound antibiotic treatment: 4-week-old healthy male C57BL / 6 mice (SPF grade) were selected as experimental animals. There were 12 mice in 3 cages in each treatment group. They had free access to food and water. The experimental period was 8 weeks.

[0091] The experimental groups are as follows:

[0092] (1) The model control group (NCD) was fed a commercially available high-fat diet (purified high-fat diet with a fat energy ratio of 45%) and was provided with normal drinking water. Except for this group, all other groups had drinking water supplemented with compound antibiotics (Abx, penicillin 1 g / L, neomycin 1 g / L, metronidazole 1 g / L, vancomycin 0.5 g / L):

[0093] (2) The high-fat diet model group (NCD+Abx) was fed with commercially available high-fat feed;

[0094] (3) The intervention group was fed a commercially available high-fat diet with the same energy content. The diet was supplemented with sesamolin (Example 1+Abx), sesamol (Example 2+Abx), sesamin (Example 3+Abx), episamolin (Example 4+Abx), pinoresinol (Example 5+Abx), sesamolinol (Example 6+Abx), menthol (Example 7+Abx), 2-epesamolinol (Example 8+Abx), sesamol triglucoside (Example 9+Abx), pinoresinol triglucoside (Example 10+Abx), a combination of sesamolin and sesamin (Example 11+Abx), a combination of sesamolin and sesamin (Example 12+Abx), a combination of sesamolin and sesamol triglucoside (Example 13+Abx), a combination of sesamolin and sesamol triglucoside (Example 14+Abx), and a combination of menthol and sesamin (Comparative Example 1+Abx) at a dose of 1000 mg / kg.

[0095] Biochemical indicators were measured: gastrointestinal hormone peptide (PYY), tumor necrosis factor-α (TNF-α), and serum lipopolysaccharide (LPS) levels were determined using an enzyme-linked immunosorbent assay (ELISA) kit.

[0096] The experimental results are shown in Table 1-2:

[0097] Table 1. Effects of different experimental groups on body weight, appetite, and gut health in a high-fat diet model.

[0098]

[0099] Note: Gastrointestinal hormone peptide (PYY), tumor necrosis factor-α (TNF-α), and lipopolysaccharide (LPS) content. * indicates that compared with NCD or CHOW, * p < 0.05, ** p < 0.01, *** p < 0.001. $ indicates that compared with the HFD group, $ p < 0.05, $$ p < 0.01, $$$ p < 0.001.

[0100] Table 2. Effects of each experimental group on body weight and appetite in the combined antibiotic treatment experiment.

[0101]

[0102] Note: * indicates that compared with NCD or CHOW, * p < 0.05, ** p < 0.01, *** p < 0.001. $ indicates that compared with the HFD group or NCD+Abx group, $ p < 0.05, $$ p < 0.01, $$$ p < 0.001.

[0103] Regarding weight control: The relative weight of the HFD group was 2.5 times that of the CHOW group (p<0.05), indicating that the obesity model induced by the high-fat diet was successfully established. The relative weight of the SON, SOL, SIN, EIN, POL, SONOL, PPL, 2EOL, SOLT, and POLT groups was significantly lower than that of the HFD group, indicating that these sesamoidin and its similar compounds and glycosides can significantly reduce mouse weight and have the potential to control weight. The relative weight of the same dose of sesamoidin combination (Examples 11-14) was reduced by 48.42%, 40.47%, 52.70%, and 36.25% respectively compared with the HFD group, and the relative weight was close to that of the CHOW group. The weight control efficacy was significantly better than these single components, showing a significant synergistic effect. However, the weight of the PPL+SIN combination group (Comparative Example 1) did not change significantly compared with the HFD group, and no significant synergistic effect was observed compared with the use of these sesamoidin alone.

[0104] Regarding appetite control: The SON, SOL, SIN, EIN, POL, SONOL, PPL, 2EOL, SOLT, and POLT groups showed significantly lower food intake compared to the HFD group, and serum levels of the appetite-suppressing hormone PYY were significantly increased, indicating that the above components can effectively control appetite. Mice using the same dose of sesame lignan composition (Examples 11-14) showed significantly lower food intake and significantly increased PYY, exhibiting a significant synergistic effect compared to the same dose of sesame lignan. However, the PPL+SIN composition group (Comparative Example 1) showed no significant change in food intake compared to the HFD group, and no significant synergistic effect was observed compared to the use of these sesame lignans alone.

[0105] Regarding the improvement of gut health: The relative body weight and food intake of mice in Examples 1-14 were not significantly different compared to the NCD+Abx group, indicating that sesame lignans affect mouse body weight and food intake through the gut microbiota. LPS is an extracellular toxin secreted by Gram-negative intestinal bacteria. Due to changes in intestinal pathways, it infiltrates into the host's bloodstream, triggering systemic low-grade inflammation. It is a host endotoxin and an important biomarker of gut health. Serum LPS and TNF-α levels in the SON, SOL, SIN, EIN, POL, SONOL, PPL, 2EOL, SOLT, and POLT groups were significantly lower than those in the HFD group, indicating that sesame lignans can significantly improve gut microbiota dysbiosis and systemic inflammation caused by a high-fat diet, thus improving gut health. Furthermore, mice with the same dose of sesame lignan composition (Examples 11-14) showed even lower LPS and TNF-α levels, demonstrating a significant synergistic effect. Furthermore, the levels of Bifidobacterium spp. in the SON, SOL, SIN, EIN, POL, SONOL, PPL, 2EOL, SOLT, and POLT groups were significantly increased compared to the HFD group, indicating that sesame lignans can significantly improve gut health. The same doses of sesame lignan compositions (Examples 11-14) also showed a synergistic effect in improving gut health. These indicators of the PPL+SIN composition (Comparative Example 1) showed no significant changes compared to the HFD group, and no significant synergistic effect was observed compared to the use of these sesame lignans alone.

[0106] Experiment Example 2

[0107] The effects of the compositions of Examples 1-14 and Comparative Example 1 on maintaining blood glucose levels and improving insulin resistance were verified. The specific methods are as follows:

[0108] High-fat diet mouse model: 4-week-old healthy male C57BL / 6 mice (SPF grade) were used as experimental animals. There were 12 mice in 3 cages in each treatment group. They had free access to food and water. The experimental period was 16 weeks.

[0109] The experimental groups are as follows:

[0110] (1) The control group (NCD) was fed a normal maintenance diet;

[0111] (2) High-fat diet model group (HFD) was fed commercially available high-fat feed.

[0112] (3) The intervention group was fed a commercially available high-fat diet with the same energy content, at 150 mg / kg body weight, by gavage daily for Examples 1-14 and Comparative Example 1, for a period of 10 weeks.

[0113] db / db mouse model: Four-week-old healthy male C57BLKS / JGpt mice were used as the normal control group (CON), and were administered the experimental solvent by gavage at a rate of 5 mL / kg body weight daily; other groups used C57BLKS / JGpt mice. dbdb diabetic mice: The diabetic control group (DBDB) was administered the experimental solvent by gavage at 5 mL / kg body weight daily; the metformin positive control group (Met) was administered metformin by gavage at 200 mg / kg body weight daily (200 mg metformin dissolved in 2.5 mL of PEG400 + 2.5 mL of physiological saline); the intervention group was administered metformin by gavage at 150 mg / kg body weight daily. Examples 1-14 and Comparative Example 1 were all fed a high-fat diet, and the experimental period was 10 weeks.

[0114] Glucose tolerance test: At the end of week 15, mice were fasted for 12 hours, followed by intraperitoneal injection of glucose solution (2 g / kg body weight). Blood glucose levels were measured in each mouse at 0, 30, 60, 90, and 120 minutes, and blood glucose change curves were plotted and the area under the blood glucose change curve (AUC) was calculated.

[0115] Biochemical assays: Serum glucose (GLU) and insulin levels were measured using commercially available standard kits or enzyme-linked immunosorbent assay (ELISA) kits. Insulin resistance index: Insulin level × blood glucose concentration / 22.5.

[0116] The results are shown in Table 3:

[0117] Table 3 Effects of each group on blood glucose and insulin resistance

[0118]

[0119] AUC: Area under the glucose tolerance test curve; GLU: Serum glucose level (mM); IRI: Insulin resistance index. * indicates comparison with NCD or CON, * p < 0.05, ** p < 0.01, *** p < 0.001. $ indicates comparison with HFD or DBDB group, $ p < 0.05, $$ p < 0.01, $$$ p < 0.001. # indicates comparison with Met, # p < 0.05, ## p < 0.01, ### p < 0.001.

[0120] As shown in Table 3, the AUC, GLU, and IRI of the SON, SOL, SIN, EIN, POL, SONOL, PPL, 2EOL, SOLT, and POLT groups were significantly lower than those of the HFD group, indicating that sesame lignans can effectively reduce the increase in blood glucose levels caused by HFD, maintain normal blood glucose levels, and improve insulin resistance. Furthermore, the AUC, GLU, and IRI of mice treated with the same dose of sesame lignan combination (Examples 11-14) were significantly lower, showing a significant synergistic effect compared to the use of sesame lignans alone at the same dose. These indicators of the PPL+SIN combination (Comparative Example 1) showed no significant changes compared to the HFD group, and no significant synergistic effect was observed compared to the use of these sesame lignans alone.

[0121] Based on the above findings, the ability of sesame lignans and their combinations to maintain blood glucose levels was specifically verified using a diabetic mouse model. As shown in Table 3, the AUC of the SON-DB, SOL-DB, SIN-DB, EIN-DB, POL-DB, SONOL-DB, PPL-DB, 2EOL-DB, SOLT-DB, and POLT-DB groups was significantly lower than that of the DBDB group, confirming that sesame lignans can effectively reduce the elevation of blood glucose levels in DBDB mice and maintain normal blood glucose levels. The AUC of mice treated with the same dose of sesame lignan combinations (Examples 11-14) was also significantly reduced, demonstrating a significant synergistic effect in maintaining blood glucose levels compared to the use of these sesame lignans alone. The AUC of the PPL+SIN-DB combination (Comparative Example 1) showed no significant change compared to the HFD group, and no significant synergistic effect was observed compared to the use of these sesame lignans alone.

[0122] Experimental Example 3

[0123] The effects of the compositions of Examples 1-14 and Comparative Example 1 on lipid-lowering and liver-damage-improving effects were verified. The specific methods are as follows:

[0124] High-fat diet mice:

[0125] Healthy male C57BL / 6 mice (SPF grade) aged 4 weeks were selected as experimental animals. There were 12 mice in 3 cages in each treatment group. They had free access to food and water. The experimental period was 10 weeks.

[0126] The experimental groups are as follows:

[0127] (1) The control group (CHOW) was fed a normal maintenance diet;

[0128] (2) The high-fat diet model group (HFD) was fed a commercial high-fat diet (purified high-fat diet with a fat energy ratio of 45%).

[0129] (3) The experimental intervention group was fed with commercial high-fat feed with equal energy, and the compositions of Examples 1-14 and Comparative Example 1 were added at 1500 mg / kg feed.

[0130] Measurement of body fat and other indicators: After anesthesia, body fat content was measured by in vivo scanning using a digital dual-energy X-ray scanner. After dissection, epididymal fat and inguinal fat were quickly dissected and weighed, and their ratios to fasting body weight were recorded as epididymal fat and inguinal fat, respectively.

[0131] Biochemical index determination: Lipids were extracted from the liver using the Folch method, dried under nitrogen, and the resulting liver lipid samples were weighed and divided by fasting body weight to determine the liver fat content. The lipids were reconstituted in ethanol, and triglyceride (TG) and total cholesterol (TC) levels were determined according to the procedures of commercially available kits. Serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC), serum aspartate aminotransferase (AST) activity, leptin (Lep), and adiponectin (Adi) were measured using commercially available standard kits or enzyme-linked immunosorbent assay (ELISA). Peroxisome proliferator-activated receptor gamma (PPARγ), a ligand-dependent transcription factor, plays an important role in maintaining triglyceride homeostasis, improving fatty liver degeneration, and visceral fat deposition. Its gene expression in the liver and extraction analysis were performed using standard real-time quantitative PCR methods.

[0132] The experimental results are shown in Table 4-5:

[0133] Table 4. Effects of each experimental group on reducing body fat

[0134]

[0135] Note: * indicates comparison with CHOW, * p < 0.05, ** p < 0.01, *** p < 0.001. $ indicates comparison with HFD group, $ p < 0.05, $$ p < 0.01, $$$ p < 0.001.

[0136] Table 5. Effects of each experimental group on lipid-lowering and liver damage.

[0137]

[0138] Note: Triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDLC), high-density lipoprotein cholesterol (HDLC, mM), serum aspartate aminotransferase activity (AST), leptin (Lep), adiponectin (Adi). * indicates comparison with CHOW, *p<0.05, **p<0.01, ***p<0.001. $ indicates comparison with HFD group, $p<0.05, $$p<0.01, $$$p<0.001.

[0139] As shown in Table 4, the body fat and epididymal fat contents of the SON, SOL, SIN, EIN, POL, SONOL, PPL, 2EOL, SOLT, and POLT groups were significantly lower than those of the HFD group, and the liver fat and groin fat were also significantly lower than those of the HFD group, indicating that sesame lignans can significantly reduce body fat content and have the potential to control body fat. Furthermore, the body fat of the same dose of sesame lignan composition (Examples 1-14) was reduced by 54.11%, 42.35%, 58.57%, and 47.90% compared to the HFD group, liver fat was reduced by 36.59%, 34.15%, 39.02%, and 36.59%, epididymal fat was reduced by 65.16%, 57.58%, 66.73%, and 67.05%, and groin fat was reduced by 57.41%, 60.09%, 69.79%, and 73.76%, indicating that the sesame lignan composition can significantly reduce body fat content, control body fat, and has a significant synergistic effect in reducing body fat. The body fat index of the PPL+SIN combination (Comparative Example 1) showed no significant change compared to the HFD group, and no obvious synergistic effect was observed compared to the use of these sesame lignans alone.

[0140] As shown in Table 5, the levels of TG, TC, LDLC, Lep, and Adi in the SON, SOL, SIN, EIN, POL, SONOL, PPL, 2EOL, SOLT, and POLT groups were significantly lower than those in the HFD group, while the relative expression level of PPARγ was significantly increased in all groups. This indicates that these sesame lignans can significantly reduce serum TG, TC, and LDLC levels and control blood lipid levels through key lipid metabolism hormones (Lep and Adi) and PPARγ, with a clear lipid-lowering pathway and mechanism. In Examples 1-14, TG, TC, and LDLC were significantly lower than those in the HFD group, showing a significant synergistic effect compared to the use of the same dose of sesame lignans alone. In Comparative Example 1, these indicators showed no significant changes compared to the HFD group, and no significant synergistic effect was observed compared to the use of these sesame lignans alone.

[0141] The aspartate aminotransferase (AST) activities in the SON, SOL, SIN, EIN, POL, SONOL, PPL, 2EOL, SOLT, and POLT groups were significantly lower than those in the HFD group by 12.06%, 10.71%, 13.19%, 18.83%, 19.73%, 20.07%, 19.95%, 21.20%, 14.77%, and 15.90%, respectively, indicating that sesame lignans can resist liver damage induced by the HFD diet. The AST activities in the Examples 1-14 groups were significantly lower than those in the HFD group by 27.17%, 23.56%, 26.72%, and 24.80%, respectively, showing a significant synergistic effect compared to the same dose of sesame lignans used alone. The AST of the composition in Comparative Example 1 showed no significant change compared to the HFD group, and no significant synergistic effect was observed compared to the use of these sesame lignans alone.

[0142] Experiment Example 4

[0143] The effects of the compositions of Examples 1-14 and Comparative Example 1 in maintaining blood pressure were verified. The specific methods are as follows:

[0144] Experimental setup:

[0145] Normal control group (NCD): Wistar Kyoto rats of the same population but without hypertension and with stable blood pressure; Hypertension model group (CON), positive control group, and experimental group: spontaneously hypertensive rats (SHRs) were selected, with 10 rats in each group, fed with normal diet, and given free access to food and water. The experimental period was 4 weeks. The hypertension model group was administered physiological saline by gavage at 5 mL / kg body weight daily (CON), the positive control group was administered captopril at gavage at 10 mg / kg body weight / day (CAP), and the dosage of sesame lignans in the experimental group was set as follows: 100 mg / kg body weight / day, administered by gavage to the compositions of Examples 1-14 and Comparative Example 1, respectively.

[0146] Blood pressure measurement: Blood pressure was measured weekly in the tail artery using the BP-2000 rat non-invasive blood pressure detection system.

[0147] The results are shown in Table 6:

[0148] Table 6. Effects of each experimental group on blood pressure in spontaneously hypertensive rats

[0149]

[0150] Note: * indicates comparison with CON, * p < 0.05, ** p < 0.01, *** p < 0.001. $ indicates comparison with CAP, $ p < 0.05, $$ p < 0.01, $$$ p < 0.001.

[0151] As shown in Table 6, the systolic blood pressure of rats in the CAP (positive control group), SON, SOL, SIN, EIN, POL, SONOL, PPL, 2EOL, SOLT, and POLT groups decreased by 23.47%, 17.13%, 13.90%, 10.93%, 21.64%, 19.96%, 18.91%, 17.55%, 15.38%, 9.08%, and 13.39% respectively compared with the CON group, while the diastolic blood pressure decreased by 24.52%, 19.05%, 14.39%, 12.33%, 24.34%, 21.97%, 24.22%, 19.05%, 18.57%, 10.34%, and 15.21% respectively compared with the CON group, indicating that sesame lignans have a significant blood pressure-lowering effect. In rats using the same dose of sesame lignan combination (Examples 11-14), systolic blood pressure decreased by 34.82%, 27.99%, 32.45%, and 33.44% compared to the CON group, and was only 0.90%, 11.46%, 4.57%, and 3.03% higher than the NCD group, respectively. Diastolic blood pressure decreased by 50.58%, 31.40%, 47.46%, and 49.47% compared to the CON group, and was only 0.61%, 39.67%, 6.97%, and 2.87% higher than the NCD group, respectively. The effect was far superior to the blood pressure-lowering ability of these sesame lignans used alone, and remained essentially at levels similar to normal rats, indicating that the sesame lignan combination has a significant synergistic blood pressure-lowering effect. In Comparative Example 1, blood pressure indicators showed no significant change compared to the CON group, and no significant synergistic effect was observed compared to the use of these sesame lignans alone.

[0152] Experimental Example 5

[0153] The specific methods for verifying the antioxidant and anti-aging effects of the compositions of Examples 1-14 and Comparative Example 1 are as follows:

[0154] Experimental Setup: Lifespan is a key indicator for evaluating the anti-aging properties of interventions. The significantly longer lifespan of nematodes compared to the natural aging lifespan indicates effective anti-aging. During the lifespan experiment, synchronized nematodes were randomly selected and placed into the drug-treated group. Each group had three parallel plates, with 30 nematodes per plate, marked as day 0. The plates were incubated at 20°C, and nematode survival was recorded daily. Nematode death and removal criteria: No reaction within 10 seconds of being lightly touched with a platinum wire; nematodes that disappeared or died after crawling out of the culture dish, or whose eggs hatched into bagworms within the nematode, were not included in the data.

[0155] The concentrations of each drug administration group are as follows: the nematode food without any treatment is recorded as the NCD group, the food containing 5 mg / mL nicotinamide mononucleotide is recorded as the NMN group, and the concentrations of Examples 1-14 and Comparative Example 1 are all 1 mM.

[0156] Antioxidant index determination: Superoxide dismutase (SOD) and catalase (CAT) activities, and malondialdehyde (MDA) content were determined strictly in accordance with the kit instructions from Nanjing Jiancheng Biotechnology Co., Ltd.

[0157] The results are shown in Table 7:

[0158] Table 7. Effects of each experimental group on the lifespan and in vivo antioxidant levels of wild-type Caenorhabditis elegans.

[0159]

[0160] Note: Superoxide dismutase (SOD), catalase (MDA) activity, and malondialdehyde (MDA) content. * indicates comparison with NCD, * p < 0.05, ** p < 0.01, *** p < 0.001. $ indicates comparison with NMN, $ p < 0.05, $$ p < 0.01, $$$ p < 0.001.

[0161] As shown in Table 7, the average lifespan of nematodes in the NMN (positive control group) and Example 1-10 groups were 1.29, 1.05, 1.06, 1.13, 1.32, 1.38, 1.18, 1.14, 1.11, 1.11, and 1.07 times that of NCD, respectively. The lifespan extension rate was 28.60%, 4.66%, 6.12%, 12.53%, 31.52%, 37.98%, 18.48%, 14.38%, 10.56%, 10.90%, and 6.69% higher than that of NCD, respectively. This indicates that sesame lignans have significant lifespan extension and anti-aging effects. The average lifespan of nematodes fed with the same dose of sesame lignan compositions (Examples 11-14) was 1.38, 1.31, 1.46, and 1.27 times that of NCD, respectively, with lifespan extension rates of 38.09%, 31.12%, 45.96%, and 26.52%, respectively. These extensions were significantly higher than the anti-aging effects of these sesame lignans used alone, indicating that the sesame lignan combinations have significant synergistic anti-aging effects. The anti-aging indicators of the compositions in Comparative Example 1 showed no significant changes compared to the NCD group, and no significant synergistic effect was observed compared to the use of these sesame lignans alone.

[0162] Correspondingly, the activities of SOD and CAT enzymes in nematodes of the NMN (positive control group) and Examples 1-10 groups were significantly enhanced compared to NCD, while the content of MDA peroxidation product was reduced, indicating that sesame lignans significantly improved the antioxidant capacity of nematodes. In contrast, the same dose of sesame lignan composition (Examples 11-14) showed significantly higher SOD and CAT enzyme activities and significantly lower MDA content compared to NCD, indicating that the composition also significantly improved the antioxidant capacity of nematodes. Furthermore, the improvement in antioxidant capacity of the composition was significantly greater than that of sesame lignans alone, indicating that the composition also has a significant synergistic antioxidant effect. These antioxidant indicators of the composition in Comparative Example 1 showed no significant changes compared to the NCD group, and no significant synergistic effect was observed compared to the use of sesame lignans alone.

[0163] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. The use of the composition of sesamin and sesamol triglucoside in the preparation of any one of the following products (1)-(6), characterized in that, The products are: (1) health foods that help maintain healthy blood sugar levels; (2) health foods that help control body fat; (3) health foods that help maintain healthy blood lipid levels; (4) health foods that help maintain healthy blood pressure levels; (5) antioxidant health foods; (6) anti-aging medicines; the mass ratio of sesamin and sesamol triglucoside in the composition is 2~8: 8~2.

Images